MaxCyte MXCT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 81.2%-0.5pp | 81.6%-6.9pp | 88.5%0.0pp | 88.5%-0.8pp | |
| Operating margin | -157.1%-24.6pp | -132.5%-15.6pp | -117%-55.2pp | -61.8%-8.2pp | |
| Net margin | -135.1%-28.9pp | -106.3%-14.4pp | -91.8%-38.6pp | -53.3%+3.0pp | |
| Returns | |||||
| Return on equity | -23.6%-4.9pp | -18.7%-3.1pp | -15.6%-6.5pp | -9.1%+3.8pp | |
| Return on invested capital | -28.4%-2.8pp | -25.5%-4.7pp | -20.8%-9.4pp | -11.4%+3.6pp | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0.2×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Liquidity | |||||
| Current ratio | 8.3×-2.6× | 10.9×+0.2× | 10.7×-5.7× | 16.4×-1.0× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $1.61-18.1% | $1.97-12.5% | $2.25-10.0% | $2.50-13.9% | |
| Valuation | |||||
| Market capitalization | $130.15M-46.8% | $438.81M-10.0% | $487.41M-12.6% | $557.58M-46.0% | |
| Price / sales | 4×-2.8× | 11.4×-0.4× | 11.8×-0.8× | 12.6×-17.9× | |
| Price / book | 0.8×-0.5× | 2.1×0.0× | 2.1×-0.1× | 2.2×-1.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are MaxCyte's profit margins?
- MaxCyte (MXCT) runs a 80.5% gross margin and a -141.8% operating margin, with a -121.2% net margin.
- Where do MaxCyte's ratios come from?
- Every ratio is computed from MaxCyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
